Silexion Therapeutics Corp (NASDAQ:SLXN) Short Interest Update

Silexion Therapeutics Corp (NASDAQ:SLXN) saw a significant decline in short interest during the month of August. As of August 31st, there was short interest totaling 14,501 shares, a decline of 87.8% from the August 15th total of 119,287 shares. Based on an average trading volume of 257,490 shares, the short-interest ratio is currently 0.1 days. Currently, 0.3% of the shares of the stock are sold short.

Analysts Set New Price Targets

Several analysts have recently commented on SLXN shares. Maxim Group cut shares of Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 29th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Silexion Therapeutics in a research note on Monday, June 15th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold”.

Silexion Therapeutics Stock Performance

Shares of Silexion Therapeutics stock traded up $0.07 during trading on Thursday, reaching $0.42. The stock had a trading volume of 118,418,259 shares, compared to its average volume of 297,799. The stock has a fifty day moving average price of $1.44 and a two-hundred day moving average price of $6.26. Silexion Therapeutics has a 52 week low of $0.34 and a 52 week high of $77.70.

Silexion Therapeutics (NASDAQ:SLXN) last posted its quarterly earnings data on Saturday, August 15th. The company reported ($5.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($21.20) by $16.03. Equities analysts predict that Silexion Therapeutics will post -45.5 earnings per share for the current fiscal year.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.